ACTIP is an independent and informal, science-based forum of European companies with an active interest in the use of animal cell technology in the development and production of biopharmaceuticals, vaccines and other preventative or therapeutic approaches. For purposes of definition, mammalian cell technology is considered to include animal cells, human cells, primary cells, insect cells and stem cells. New developments in other cell types are reported on regularly.
ACTIP objectives and scope
Intensive networking among the member companies, with SMEs and academics working in the field to increase European competitiveness.
Directing the attention on initiation, generation and accomplishment of work and research projects sponsored by the European Commission.
Focusing on challenges
Join industry and academics for focusing on technological and applied-oriented challenges.
Staying up to date
Following new aspects in research, development and technology.
Supporting young scientists
Speaking up for an increased recognition of young scientists in the field of animal cell technology and introducing young scientists working in the field of animal cell technology to the ACTIP network by the ACTIP Fellowship Award.
ACTIP Steering Committee
Day to day business is taken care of by a Steering Committee, which is elected every two years from the membership. Here is the current Steering Committee:
Dr. Matthieu Stettler
Dr. Martin Wisher
Merck Life Science
Dr. Thomas Link
Dr. Holger Lübben
GSK Vaccines GmbH
Dr. Lars Dreesmann
Boehringer Ingelheim Pharma
Dr. Christine Mitchell-Logean
Dr. Nienke Vriezen
Dr. Erwin van Vliet
The Executive Secretary follows up actions, maintains contacts with European organizations, prepares meetings and is the first point of contact for information.